Expanded Access to ABBV-8E12
August 16, 2019 updated by: AbbVie
This is an expanded access program (EAP) for eligible participants.
This program is designed to provide access to ABBV-8E12 prior to approval by the local regulatory agency.
Availability will depend on territory eligibility.
Participating sites will be added as they apply for and are approved for the EAP.
A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Study Overview
Status
No longer available
Intervention / Treatment
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
November 14, 2018
First Submitted That Met QC Criteria
November 14, 2018
First Posted (Actual)
November 16, 2018
Study Record Updates
Last Update Posted (Actual)
August 20, 2019
Last Update Submitted That Met QC Criteria
August 16, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C19-364
- C19-921 (Other Grant/Funding Number: AbbVie)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)
-
University of California, San FranciscoTau Consortium; CBD SolutionsCompletedProgressive Supranuclear Palsy (PSP) | Corticobasal Degeneration (CBD) | Corticobasal Syndrome (CBS) | Primary Four Repeat Tauopathies (4RT)United States
-
Technical University of MunichRecruitingCorticobasal Syndrome (CBS)Germany
-
University of California, San FranciscoNational Institutes of Health (NIH); National Institute on Aging (NIA)Active, not recruitingProgressive Supranuclear Palsy (PSP) | Corticobasal Degeneration (CBD) | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Corticobasal Syndrome (CBS) | Cortical-basal Ganglionic Degeneration (CBGD) | Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)United States, Canada
-
Johns Hopkins UniversityRecruitingUpper Extremity Dysfunction | Corticobasal SyndromeUnited States
-
University of California, San FranciscoNational Institute of Neurological Disorders and Stroke (NINDS); National Center... and other collaboratorsCompletedAmyotrophic Lateral Sclerosis (ALS) | Progressive Supranuclear Palsy (PSP) | Corticobasal Degeneration (CBD) | FTLD | Frontotemporal Dementia (FTD) | PPA Syndrome | Behavioral Variant Frontotemporal Dementia (bvFTD) | Semantic Variant Primary Progressive Aphasia (svPPA) | Nonfluent Variant Primary Progressive... and other conditionsUnited States, Canada
-
Johns Hopkins UniversityRecruitingCorticobasal Degeneration | Corticobasal Syndrome | Pain, NeuropathicUnited States
-
University of California, San FranciscoTerminatedNonfluent Aphasia, Progressive | Primary Tauopathies | Corticobasal Degeneration Syndrome | Frontotemporal Lobar Degeneration With Tau Inclusions | MAPT Mutation Carriers, Symptomatic | Traumatic Encephalopathy SyndromeUnited States
-
Washington University School of MedicineAssociation of Frontotemporal Degeneration; Tau ConsortiumCompletedProgressive Supranuclear Palsy (PSP) | Corticobasal Degeneration (CBD) | Frontotemporal Dementia (FTD MAPT Mutation)United States
-
Ludwig-Maximilians - University of MunichActive, not recruitingAlzheimer Disease | Corticobasal Syndrome
-
Mayo ClinicNational Institute of Neurological Disorders and Stroke (NINDS); National Institute... and other collaboratorsRecruitingAmyotrophic Lateral Sclerosis | Progressive Supranuclear Palsy (PSP) | Corticobasal Degeneration (CBD) | GRN Related Frontotemporal Dementia | Behavioral Variant Frontotemporal Dementia (bvFTD) | Semantic Variant Primary Progressive Aphasia (svPPA) | Nonfluent Variant Primary Progressive Aphasia... and other conditionsUnited States, Canada
Clinical Trials on ABBV-8E12
-
AbbVieCompletedAlzheimer's DiseaseUnited States, Australia, Belgium, Canada, Denmark, Finland, Italy, Netherlands, New Zealand, Spain, Sweden
-
AbbVieTerminatedAlzheimer's DiseaseUnited States, Australia, Belgium, Canada, Denmark, Finland, Italy, New Zealand, Spain, Sweden
-
AbbVieTerminatedProgressive Supranuclear PalsyUnited States, Australia, Canada, France, Germany, Italy, Japan, Spain
-
AbbVieCompletedProgressive Supranuclear Palsy (PSP)United States
-
Idorsia Pharmaceuticals Ltd.TerminatedPulmonary Arterial HypertensionUnited States, France, Switzerland
-
AbbVieTerminatedProgressive Supranuclear Palsy (PSP)United States, Australia, Canada, Italy, Japan
-
C2N DiagnosticsCompletedProgressive Supranuclear PalsyUnited States
-
AbbVieCompletedCystic FibrosisUnited States, Belgium, Canada, Czechia, France, Hungary, Netherlands, New Zealand, Poland, Slovakia, United Kingdom, Serbia
-
AbbVieTerminated
-
AbbVieCompletedCoronaVirus Disease-2019 (COVID-19)United States, Hungary, Israel, Netherlands, Puerto Rico